A Study of Capecitabine (Xeloda) in Participants With Advanced or Metastatic Gastric Cancer
Not Applicable
- Registration Number
- PER-018-04
- Lead Sponsor
- PRODUCTOS ROCHE Q.F.S.A.,
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Adults 18 to 75 years of age
Advanced and/or metastatic gastric cancer with at least 1 measurable lesion
Exclusion Criteria
Uncontrolled infection
Evidence of central nervous system (CNS) metastases
History of other malignancy within the last 5 years, except cured basal cell cancer of the skin or cured in-situ cancer of the uterine cervix
Radiation therapy or major surgery within 4 weeks of study drug
Previous chemotherapy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <br>Outcome name:Tiempo hasta la progresion de la enfermedad<br>Measure:Time to disease progression<br>Timepoints:Up to approximately 7.3 years<br>
- Secondary Outcome Measures
Name Time Method <br>Outcome name:Overall survival<br>Measure:Overall survival<br>Timepoints:Up to approximately 7.3 years<br>